Class II MHC antigens in early rheumatoid arthritis in Bath (UK) and Madrid (Spain)

被引:28
作者
Balsa, A
Minaur, NJ
Pascual-Salcedo, D
McCabe, C
Balas, A
Fiddament, B
Vicario, JL
Cox, NL
Martín-Mola, E
Hall, ND
机构
[1] Univ Madrid, Hosp La Paz, Rheumatol Unit, Madrid 28046, Spain
[2] Univ Madrid, Hosp La Paz, Immunol Unit, Madrid 28046, Spain
[3] Univ Bath, RNHRD, Bath Inst Rheumat Dis, Bath Early Synovitis Grp, Bath, Avon, England
[4] Univ Bath, Dept Pharm & Pharmacol, Bath, Avon, England
[5] Ctr Transfus Comunidad Madrid, Madrid, Spain
关键词
rheumatoid arthritis; early; class II MHC; UK; Spain;
D O I
10.1093/rheumatology/39.8.844
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. A number of studies have indicated that rheumatoid arthritis (RA) is a less severe disease in Mediterranean countries than in Northern Europe, We investigated whether differences in the frequency of class II MHC antigens might contribute to this variation in disease severity. Methods. Typing at HLA-DR and -DQ loci was carried out at low and high resolutions by polymerase chain reaction amplification in patients with early RA of less than 6 months' duration (68 patients in Madrid and 68 in Bath) and in control subjects (929 in Madrid and 226 in Bath). Only ethnic Spanish and British individuals were included as patients and controls. Results. Shared epitope (SE) alleles represented 19.8 and 28.9% of the total number of class II MHC alleles in controls from Madrid and Bath respectively (P = 0.00001), this difference being largely due to increased numbers of DRB1*0401 individuals in the British subjects (P = 0.0000001). Analysis of the patients showed the expected increase in SE alleles when compared with their respective control groups (Madrid, 31.6 vs 19.8%; Bath, 42.6 vs 28,9%). In Bath the SE was mainly encoded by HLA-DR4 alleles (74.1%), while in Madrid it was encoded almost equally by DR4 (51.1%) and DR1 (44.7%) alleles. The risk of developing RA in carriers of SE alleles was similar in the two cities (Bath, odds ratio 1.83, 95% confidence interval 1.23-2.78, Madrid, odds ratio 1.87, 95% confidence interval 1.25-2.77), and was largely accounted for by HLA-DRB1*0401 alleles. Conclusion. We conclude that rheumatoid patients in Bath differ from their Spanish counterparts in class II antigen expression and allele frequency. This may be explained partly by genetic differences between the control populations in the two centres, and may help to explain the greater incidence of more severe rheumatoid disease expression seen in RA patients In the UK.
引用
收藏
页码:844 / 849
页数:6
相关论文
共 53 条
[41]   ABSENCE OF AN ASSOCIATION BETWEEN HLA-DRB1-ASTERISK-04 AND RHEUMATOID-ARTHRITIS IN NEWLY-DIAGNOSED CASES FROM THE COMMUNITY [J].
THOMSON, W ;
PEPPER, L ;
PAYTON, A ;
CARTHY, D ;
SCOTT, D ;
OLLIER, W ;
SILMAN, A ;
SYMMONS, D .
ANNALS OF THE RHEUMATIC DISEASES, 1993, 52 (07) :539-541
[42]   ASSOCIATION OF HLA-DR4 WITH A MORE PROGRESSIVE DISEASE COURSE IN PATIENTS WITH RHEUMATOID-ARTHRITIS - RESULTS OF A FOLLOW-UP-STUDY [J].
VANZEBEN, D ;
HAZES, JMW ;
ZWINDERMAN, AH ;
CATS, A ;
SCHREUDER, GMT ;
DAMARO, J ;
BREEDVELD, FC .
ARTHRITIS AND RHEUMATISM, 1991, 34 (07) :822-830
[43]  
Verweij CL, 1998, BRIT J RHEUMATOL, V37, P923
[44]   Polymorphism at the TNF loci in rheumatoid arthritis [J].
Vinasco, J ;
Beraun, Y ;
Nieto, A ;
Fraile, A ;
Mataran, L ;
Pareja, E ;
Martin, J .
TISSUE ANTIGENS, 1997, 49 (01) :74-78
[45]  
Wakitani S, 1997, BRIT J RHEUMATOL, V36, P630
[46]   HOMOZYGOSITY FOR THE HLA-DRB1 ALLELE SELECTS FOR EXTRAARTICULAR MANIFESTATIONS IN RHEUMATOID-ARTHRITIS [J].
WEYAND, CM ;
XIE, CP ;
GORONZY, JJ .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 89 (06) :2033-2039
[47]   ASSOCIATION OF HLA-DW16 WITH RHEUMATOID-ARTHRITIS IN YAKIMA INDIANS - FURTHER EVIDENCE FOR THE SHARED EPITOPE HYPOTHESIS [J].
WILLKENS, RF ;
NEPOM, GT ;
MARKS, CR ;
NETTLES, JW ;
NEPOM, BS .
ARTHRITIS AND RHEUMATISM, 1991, 34 (01) :43-47
[48]   THE MOLECULAR-BASIS OF SUSCEPTIBILITY TO RHEUMATOID-ARTHRITIS [J].
WINCHESTER, R .
ADVANCES IN IMMUNOLOGY, VOLUME 56, 1994, 56 :389-466
[49]  
WORDSWORTH BP, 1992, SPRINGER SEMIN IMMUN, V14, P59
[50]  
WORDSWORTH P, 1992, AM J HUM GENET, V51, P585